Ex vivo drug susceptibility and resistance mediating genetic polymorphisms of Plasmodium falciparum in Bobo-Dioulasso, Burkina Faso
Antimicrobial Agents and Chemotherapy · 2024
DOI: 10.1128/aac.01534-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von A Fabrice Somé und 14 weiteren Autor:innen. Beteiligte Einrichtung: Institut de Recherche en Sciences de la Santé, Direction Régionale de l'Ouest, Bobo-Dioulasso, Burkina Faso. Hauptthemen laut MEDLINE: Antimalarials, Malaria, Falciparum, Folic Acid Antagonists, Malaria. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, Foundation for the National Institutes of Health, HHS | National Institutes of Health.
Abstract (Originalsprache)
Malaria remains a leading cause of morbidity and mortality in Burkina Faso, which utilizes artemether–lumefantrine as the principal therapy to treat uncomplicated malaria and seasonal malaria chemoprevention with monthly sulfadoxine–pyrimethamine plus amodiaquine in children during the transmission season. Monitoring the activities of available antimalarial drugs is a high priority. We assessed the ex vivo susceptibility of Plasmodium falciparum to 11 drugs in isolates from patients presenting with uncomplicated malaria in Bobo-Dioulasso in 2021 and 2022. IC 50 values were derived using a standard 72 h growth inhibition assay. Parasite DNA was sequenced to characterize known drug resistance-mediating polymorphisms. Isolates were generally susceptible, with IC 50 values in the low-nM range, to chloroquine (median IC 50 10 nM, IQR 7.9–24), monodesethylamodiaquine (22, 14–46) piperaquine (6.1, 3.6–9.2), pyronaridine (3.0, 1.3–5.5), quinine (50, 30–75), mefloquine (7.1, 3.7–10), lumefantrine (7.1, 4.5–12), dihydroartemisinin (3.7, 2.2–5.5), and atovaquone (0.2, 0.1–0.3) and mostly resistant to cycloguanil (850, 543–1,290) and pyrimethamine (33,200, 18,400–54,200), although a small number of outliers were seen. Considering genetic markers of resistance to aminoquinolines, most samples had wild-type PfCRT K76T (87%) and PfMDR1 N86Y (95%) sequences. For markers of resistance to antifolates, established PfDHFR and PfDHPS mutations were highly prevalent, the PfDHPS A613S mutation was seen in 19% of samples, and key markers of high-level resistance (PfDHFR I164L; PfDHPS K540E) were absent or rare (A581G). Mutations in the PfK13 propeller domain known to mediate artemisinin partial resistance were not detected. Overall, our results suggest excellent susceptibilities to drugs now used to treat malaria and moderate, but stable, resistance to antifolates used to prevent malaria.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institut de Recherche en Sciences de la Santé, Direction Régionale de l'Ouest, Bobo-Dioulasso, Burkina Faso.
- Department of Medicine, University of California, San Francisco, California, USA.
- Institut des Sciences et Techniques, Bobo-Dioulasso, Burkina Faso.
- Department of Pathology and Laboratory Medicine, Warren Alpert Medical School, Brown University, Providence, Rhode Island, USA.
- Department of Natural Sciences and Mathematics, Dominican University of California, San Rafael, California, USA.
ORCID-Profile: A Fabrice Somé, Melissa D Conrad, Philip J Rosenthal, Roland A Cooper
Förderung
- NIAID NIH HHS
- Foundation for the National Institutes of Health
- HHS | National Institutes of Health
- Medicines for Malaria Venture
Zitieren
APA
Somé, A. F., Conrad, M. D., Kabré, Z., Fofana, A., Yerbanga, R. S., Bazié, T., Neya, C., Somé, M., Kagambega, T. J., Legac, J., Garg, S., Bailey, J. A., Ouédraogo, J. B., Rosenthal, P. J., & Cooper, R. A. (2024). Ex vivo drug susceptibility and resistance mediating genetic polymorphisms of Plasmodium falciparum in Bobo-Dioulasso, Burkina Faso. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01534-23
Vancouver
Somé AF, Conrad MD, Kabré Z, Fofana A, Yerbanga RS, Bazié T, et al. Ex vivo drug susceptibility and resistance mediating genetic polymorphisms of Plasmodium falciparum in Bobo-Dioulasso, Burkina Faso. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.01534-23
BibTeX
@article{Som2024,
author = {Somé, A Fabrice and Conrad, Melissa D and Kabré, Zachari and Fofana, Aminata and Yerbanga, R Serge and Bazié, Thomas and Neya, Catherine and Somé, Myreille and Kagambega, Tegawinde Josue and Legac, Jenny and Garg, Shreeya and Bailey, Jeffrey A and Ouédraogo, Jean-Bosco and Rosenthal, Philip J and Cooper, Roland A},
title = {Ex vivo drug susceptibility and resistance mediating genetic polymorphisms of Plasmodium falciparum in Bobo-Dioulasso, Burkina Faso},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2024},
doi = {10.1128/aac.01534-23}
}
EUVIMED